STAND Clinical Trial Results Published
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal of Tuberculosis and Lung Disease. The STAND trial tested the potential of the novel three-drug regimen, PaMZ, to shorten and simplify treatment in both drug-sensitive tuberculosis (TB) and multidrug-resistant TB patients. The STAND trial was paused in September of 2015 and did not resume. A total of 284 patients were enrolled in the trial, which was conducted at 26 sites across 8 countries. Participants who completed treatment received six months of follow up, as well as additional monitoring for two years, as per the study design.